| 规格: | 98% |
| 分子量: | 1581.85 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
Background:
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC comprises an antibody conjugated via a linker to a PROTAC. PAC extracts from patent WO2017201449A1, compound LP2. PAC is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
